Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Vlad Ratziu, Fréderic Charlotte, Carole Bernhardt, Philippe Giral, Marine Halbron, Gilles LeNaour, Agnès Hartmann‐Heurtier, Eric Bruckert, Thierry Poynard, LIDO Study Group – 25 January 2010 – Short‐term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. Longer treatment might result in additional improvement. After a 1‐year randomized trial, 53 patients underwent a control liver biopsy and were enrolled in an open‐label extension trial of rosiglitazone (RSG), 8 mg/day for 2 additional years.